Business Wire

EHL Awarded for Revamp of Its Flagship Bachelor

26.11.2019 17:11:00 EET | Business Wire | Press release

Share

EHL has been awarded the World Hospitality Awards (WHA) prize for “Innovation in Education”, in recognition of its revamped Bachelor of Science in International Hospitality Management which leverages the full power of the multi-campus education group.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005522/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: EHL)

First international campus
Establishing an international presence was a paramount factor in EHL’s plans to enrich its students’ learning and broaden their perspectives. With such clear intent to expand into emerging hospitality markets, EHL Group has been authorized to deliver its Bachelor of Science in International Hospitality Management in Singapore. EHL Campus (Singapore)1 will receive its first cohort in the fall of 2021. In the meantime, the Group plans to deliver short courses on site as early as summer 2020.

“We very much look forward to expanding our connection to the local community and participate in this thriving environment. It is with enthusiasm and conviction that we embark on this new adventure. Our commitment to the local economy will start on-campus and extend throughout the country, as we hope to strengthen our existing ties to the Singaporean hospitality industry”, said EHL Group CEO Michel Rochat.

Candidates can visit: https://singapore.ehl.edu and apply to start their Preparatory Year at EHL Campus Lausanne in September 2020 and then begin their Bachelor course as the first cohort at EHL Campus (Singapore) in September 2021.

1 Bachelor, 2 Pathways, 3 Campuses
The novel organization of EHL’s offering, which the WHA has awarded, is best represented by the new slogan 1 Bachelor, 2 pathways, 3 campuses. 1 degree, representing the world-renowned Bachelor degree which is the foundation of EHL’s global recognition, 2 pathways, as EHL Passugg students who are studying to get a professional diploma are now given the opportunity to extend their studies and work towards a university-level degree. Finally, 3 campuses thanks to the third South-East Asian campus in Singapore, in addition to the Swiss campuses in Lausanne and Passugg.

“EHL has become a truly global education provider and now sets itself further apart by enabling students to aspire for bigger, better things either in Switzerland or abroad. We are proud of being recognized for our pioneering efforts and very much look forward to the new global alliances and partnerships that will stem from our Asian foothold”, concluded Michel Rochat.

1EHL Campus (Singapore) is registered as a private education institution in Singapore under the Private Education Act, Enhanced Registration Framework (ERF), Registration No 201731189N, and has received EduTrust Certification Scheme (Certification number EDU-2-2124, valid from June 14 2019 to June 13 2023).

About EHL Group

www.ehl.edu

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

EHL Group
Sherif Mamdouh | External Communications Manager
communication@ehl.ch | +41 21 785 10 53

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye